FindTrial
Sign In

Role of L-arginine in the treatment of reduced amniotic fluid

"Role of L-arginine in the treatment of oligohydramnios - A Randomized Controlled trial" - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/062282
Enrollment
60
Registered
2024-02-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O410- Oligohydramnios

Interventions

Intervention1: L-argenine in oligohydramnios: one sachet of L-arginine in one glass of water once a day orally till 37 weeks POG is given to patients with oligohydramnios to assess the effect on amnio

Sponsors

Dr Deepita vais
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. From 28-37 weeks POG. 2. Singleton pregnancy. 3. AFI less than 8. 4. Membrane should be intact.

Exclusion criteria

Exclusion criteria: 1. Smoking. 2. Foetal malformation. 3. Severe pre- eclampsia. 4 . Abnormal foetal Doppler. 5. Premature rupture of membrane.

Design outcomes

Primary

MeasureTime frame
To assess the role of L-arginine in the treatment of oligohydramnios.Timepoint: Every week till delivery—

Secondary

MeasureTime frame
To determine the efficacy of L-arginine as a treatment modality in oligohydramniosTimepoint: Every week till delivery—

Countries

India

Contacts

Public ContactDeepita Vais

Rohilkhand medical college and hospital

shosa@rediffmail.com9319854442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026